What Do German Molecular Tumor Boards Recommend in Patients with PIK3CA-Mutated Tumors? Launch and First Results from the German Transsectoral Molecular Tumor Board Exchange Platform Deutschland

Ina Pretzell; Alexander Desuki; Annalen Bleckmann; Sonja Loges; Anke Reinacher-Schick; C Benedikt Westphalen; Sebastian Lange; TEAM-D Participants

doi:10.1159/000539217

What Do German Molecular Tumor Boards Recommend in Patients with PIK3CA-Mutated Tumors? Launch and First Results from the German Transsectoral Molecular Tumor Board Exchange Platform Deutschland

Oncol Res Treat. 2024;47(9):410-419. doi: 10.1159/000539217. Epub 2024 May 7.

Authors

Ina Pretzell¹, Alexander Desuki², Annalen Bleckmann^{3

4}, Sonja Loges⁵, Anke Reinacher-Schick⁶, C Benedikt Westphalen^{7

8}, Sebastian Lange⁹; TEAM-D Participants

Affiliations

¹ West German Cancer Center, University Hospital Essen, Essen, Germany.
² University Cancer Center Mainz, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
³ Department of Medicine A for Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany.
⁴ West German Cancer Center, University Hospital Muenster, Muenster, Germany.
⁵ Department of Personalized Oncology, University Hospital Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
⁶ Department of Hematology and Oncology, St. Josef Hospital, Ruhr University, Bochum, Germany.
⁷ Comprehensive Cancer Center Munich and Department of Medicine III, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, Germany.
⁸ German Cancer Consortium (DKTK), partner site Munich, Munich, Germany.
⁹ TUM School of Medicine and Health, Department of Clinical Medicine - Clinical Department for Internal Medicine II, University Medical Center, Technical University of Munich, Munich, Germany.

PMID: 38714183
DOI: 10.1159/000539217

Abstract

Introduction: Comprehensive molecular tumor profiling is widely used in the management of patients with cancer. Molecular tumor boards devise treatment strategies based on testing results. In this setting, the Transsectoral Molecular Tumor Board exchange platform Deutschland (TEAM-D) aims to drive peer-to-peer exchange to connect experts in the field.

Methods: During the first virtual TEAM-D meeting, participants from 16 German universities and 5 nonacademic institutions discussed five cases with PIK3CA hotspot mutations. Furthermore, an illustrative case vignette was presented.

Results: Overall, German caregivers show restraint in administering off-label PIK3CA inhibitor and favor clinical trials in this setting.

Conclusion: In the setting of precision oncology, TEAM-D enables virtual case discussion across the different sectors of the German healthcare system. Based on the example of PIK3CA hotspot mutations, TEAM-D demonstrated the value of integrating knowledge from different healthcare professionals.

Keywords: Molecular diagnostics; Molecular tumor board; PIK3CA; Precision oncology; Targeted treatments.

MeSH terms

Class I Phosphatidylinositol 3-Kinases* / genetics
Female
Germany
Humans
Male
Middle Aged
Molecular Targeted Therapy
Mutation*
Neoplasms / genetics
Neoplasms / therapy
Precision Medicine / methods

Substances

Class I Phosphatidylinositol 3-Kinases
PIK3CA protein, human